Cariprazine - Mapi Pharma
Latest Information Update: 11 Mar 2024
At a glance
- Originator Mapi Pharma
- Class
- Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2B receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Schizophrenia
Most Recent Events
- 06 Feb 2024 Cariprazine - Mapi Pharma is available for licensing as of 06 Feb 2024. https://mapi-pharma.com/about/our-strategy/
- 05 Feb 2024 Preclinical trials in Schizophrenia in Israel (Parenteral), prior to January 2024 (Mapi Pharma pipeline, January 2024)